The prospects of cariprazine in the treatment of schizophrenia

[1]  S. Durgam,et al.  Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study , 2017, CNS Spectrums.

[2]  P. Czobor,et al.  Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial , 2017, The Lancet.

[3]  F. Tarazi,et al.  Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine , 2017, CNS Spectrums.

[4]  S. Stahl.  Mechanism of action of cariprazine , 2016, CNS Spectrums.

[5]  B. Kiss,et al.  The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia , 2016, European Neuropsychopharmacology.

[6]  B. Kiss,et al.  Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology , 2016, European Neuropsychopharmacology.

[7]  P. Ferguson,et al.  The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. , 2016, The Journal of clinical psychiatry.

[8]  R. Coveñas,et al.  New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine , 2015, Therapeutics and clinical risk management.

[9]  B. Kiss,et al.  Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats , 2013, Psychopharmacology.

[10]  Eva Schmidt,et al.  Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile , 2010, Journal of Pharmacology and Experimental Therapeutics.